drugset / Trial / NCT00421317
Imatinib in Adult Patients With Metastatic Ocular Melanoma
Phase 2
Terminated
13 enrolled
Centre Oscar Lambret
National Cancer Institute, France · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Timeline
- Start
- 2005-12
- Primary completion
- 2009-11-15
- Completion
- 2009-11-15
Outcome
Outcome not reported
Stopped: “Study stopped at the end of the first step”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 800 mg | — |